logo
  

GSK : Preclinical Data Show Sotrovimab Retains Activity Against Omicron Mutations

GlaxoSmithKline plc. (GSK,GSK.L) and Vir Biotechnology Inc. (VIR) said preclinical data demonstrated that sotrovimab, an investigational monoclonal antibody, retains activity against key mutationsof the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.

The companies said that the data will be confirmed by further in vitro pseudo-virus testing. They plans to provide an update on it by the end of 2021.

GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet. WhatsApp, an instant messaging app owned by Meta Platforms, has launched a new desktop app for Windows users. The company is also developing an app native to Mac operating systems. Till now, WhatsApp Desktop users have been using its web-based desktop app i.e., WhatsApp Desktop, or browser-based app, i.e., WhatsApp Web. They were using the old Electron technology.
Follow RTT